RPI Blog PM360: How COVID Has Reshaped the Clinical Trial Regulatory Landscape

The concept of patient centricity is hardly new, but in recent months it has assumed new urgency as industry and regulators have had to adapt to an evolving landscape. The evolution is spurring substantial changes in how clinical trials are developed and implemented, as regulators revise their processes and issue updated guidance documents to encourage speed and efficiency while still ensuring patient safety. The U.S. Food and Drug Administration (FDA) has been at the forefront of recent changes, notably throughRead moreThe post PM360: How COVID Has Reshaped the Clinical Trial Regulatory Landscape appeared first on Regulatory Professionals.